LEADER 04428nam 2201117z- 450 001 9910619465503321 005 20231214133656.0 010 $a3-0365-5222-7 035 $a(CKB)5670000000391619 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/93214 035 $a(EXLCZ)995670000000391619 100 $a20202210d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNovel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (206 p.) 311 $a3-0365-5221-9 330 $aPatient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ?Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action?, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges. 517 $aNovel Anti-cancer Agents and Cellular Targets and Their Mechanism 606 $aTechnology: general issues$2bicssc 606 $aHistory of engineering & technology$2bicssc 610 $amicrotubule acetylation 610 $atriple-negative breast cancer 610 $aanti-cancer agent 610 $aapoptosis 610 $aK562 610 $a8-hydroxydaidzein 610 $aautophagy 610 $aBCR-ABL 610 $aMAPK 610 $aNF-?B 610 $ac-myc 610 $aRNA interference 610 $asiRNA 610 $aoncogene 610 $agene silencing 610 $aexpression 610 $ananosystems 610 $aCytochrome P450 610 $aCYP1A1 610 $aCYP1B1 610 $aCYP2W1 610 $abreast cancer 610 $aprodrug 610 $abioprecursor 610 $aduocarmycin 610 $aphortress 610 $aAQ4N 610 $a5-FU resistance 610 $acolorectal cancer 610 $adrug repurposing 610 $aGenomics of Drug Sensitivity in Cancer 610 $aConnectivity Map 610 $aanticancer drug 610 $aB-lactam steroid alkylators 610 $asynthetic lethality 610 $apoly (ADP-ribose) polymerase inhibitors 610 $aovarian cancer 610 $ahybrid steroidal alkylating agents 610 $amigration 610 $ainvasion 610 $aglioblastoma 610 $aCCN1 610 $amesenchymal-amoeboid transition 610 $abiomarker 610 $aHepG2 610 $aHuh7 610 $aisatin sulfonamides 610 $aangiogenesis 610 $acancer hallmarks 610 $amolecular docking 610 $aEGFR tyrosine kinase inhibitor 610 $aphoton upconversion 610 $atriplet-triplet annihilation 610 $ain vivo imaging 610 $aPLGA 610 $ananoparticles 610 $aaffibody molecule 610 $ahuman epidermal growth factor receptor 3 (HER3) 610 $aBxPC-3 610 $aemtansine 610 $aDM1 610 $aalbumin binding domain 610 $aaffibody drug conjugate (AffiDC) 615 7$aTechnology: general issues 615 7$aHistory of engineering & technology 700 $aAllison$b Simon J$4edt$01329056 702 $aAllison$b Simon J$4oth 906 $aBOOK 912 $a9910619465503321 996 $aNovel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action$93039279 997 $aUNINA